Viracta Therapeutics (VIRX) Receives a Buy from Oppenheimer
In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on Viracta Therapeutics (VIRX), with a price target of $36.00. The company’s shares closed last Wednesday at $12.13.
According to TipRanks.com, Singh is a 5-star analyst with an average return of 16.6% and a 50.7% success rate. Singh covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Catabasis Pharmaceuticals, and Alexion Pharmaceuticals.
Viracta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.50, representing a 175.5% upside. In a report issued on June 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.